AbCellera Biologics Inc (ABCL) concluded trading on Wednesday at a closing price of $4.22, with 6.97 million shares of worth about $29.42 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 34.82% during that period and on July 09, 2025 the price saw a gain of about 8.48%. Currently the company’s common shares owned by public are about 298.36M shares, out of which, 223.95M shares are available for trading.
Stock saw a price change of 20.92% in past 5 days and over the past one month there was a price change of 72.95%. Year-to-date (YTD), ABCL shares are showing a performance of 56.88% which increased to 44.03% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.89 but also hit the highest price of $4.11 during that period. The average intraday trading volume for AbCellera Biologics Inc shares is 5.45 million. The stock is currently trading 19.67% above its 20-day simple moving average (SMA20), while that difference is up 55.09% for SMA50 and it goes to 53.91% higher than SMA200.
AbCellera Biologics Inc (NASDAQ: ABCL) currently have 298.36M outstanding shares and institutions hold larger chunk of about 41.08% of that.
The stock has a current market capitalization of $1.26B and its 3Y-monthly beta is at 0.61. It has posted earnings per share of -$0.57 in the same period. It has Quick Ratio of 10.15 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABCL, volatility over the week remained 8.56% while standing at 9.46% over the month.
Stock’s fiscal year EPS is expected to drop by -11.29% while it is estimated to increase by 18.84% in next year. EPS is likely to grow at an annualized rate of 0.83% for next 5-years, compared to annual growth of -107.74% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on July 07, 2025 offering an Outperform rating for the stock and assigned a target price of $5 to it. On February 22, 2024, The Benchmark Company Upgrade their recommendations, while on December 05, 2023, KeyBanc Capital Markets Initiated their ratings for the stock with a price target of $6. Stock get a Hold rating from The Benchmark Company on November 06, 2023.
